Johnson & Johnson quarterly profit beats on higher
pharma unit sales
Send a link to a friend
[July 17, 2018]
(Reuters) - Johnson & Johnson
<JNJ.N> on Tuesday topped analysts' estimates for quarterly profit and
revenue, driven by higher sales of rare-disease treatments from its
acquisition of Actelion and cancer drugs Zytiga and Darzalex.
Sales across the company's three main units rose, with the
pharmaceutical business surging nearly 20 percent to $10.35 billion,
accounting for almost half of total sales in the second quarter.
The company's shares were volatile in premarket trading, recovering from
an initial drop to trade up 1.4 percent at $126.46.
J&J has vowed to appeal a Missouri jury verdict that earlier this month
ordered the company to pay a record $4.69 billion to 22 women, who had
claimed their cancer was caused by J&J talc products.
The company is facing about 9,000 lawsuits alleging that its talc-based
products, including its baby powder, caused ovarian cancer and
mesothelioma, a rare cancer linked to asbestos. The company has denied
that the products contain asbestos or cause cancer of any kind.
Net earnings rose to $3.95 billion, or $1.45 per share, in the second
quarter, from $3.83 billion, or $1.40 per share, a year earlier.
Excluding items, the company reported a profit of $2.10 per share,
beating analysts' average estimate of $2.07.
Total sales rose to $20.83 billion from $18.84 billion a year ago, above
analysts' estimates of $20.39 billion.
[to top of second column]
The Johnson and Johnson logo is seen at an office building in
Singapore January 17, 2018. REUTERS/Thomas White
International revenue for J&J rose 11.8 percent in the reported quarter, and
accounted for nearly half of its total sales.
The healthcare conglomerate said it expects full-year sales of $80.5 billion to
$81.3 billion, compared with a prior estimate of $81.0 billion to $81.8 billion.
The company cited a strengthening dollar for the trim.
Analysts had expected full-year profit of $8.12 per share and sales of $81.47
billion, according to Thomson Reuters I/B/E/S.
J&J said it now expects adjusted earnings of $8.07 to $8.17 per share, compared
with an earlier forecast of $8.00-$8.20 per share.
(Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila)
[© 2018 Thomson Reuters. All rights
Copyright 2018 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.